Stoke Therapeutics earnings: Investors brace for revenue test
Stoke Therapeutics (STOK) reports Q3 earnings, with analysts expecting a $0.93 loss per share on $8.21M revenue, down 12% sequentially. The company is developing RNA medicines, with key updates on zorevunersen for Dravet syndrome and STK-002 for optic atrophy. All 14 analysts rate it a Strong Buy with a $46.46 target, implying 75.9% upside. Investors will focus on revenue trends and clinical progress.
How this was made
The 30-second read
Why it matters
The guidance suggests a slowdown, which may trigger a re‑rating by analysts and affect the stock's valuation multiples.
Market read
The guidance release is the primary catalyst for short‑term price movement in STOK.
What to watch
Potential upside from upcoming Phase 3 readout and NDA filing could offset short‑term revenue dip.
Background
Stoke Therapeutics is a pre‑commercial biotech focused on RNA medicines, recently noted for surprising revenue performance in Q2.
Ticker impact
The article provides the first public forecast of Stoke Therapeutics' Q3 earnings, including expected loss per share and revenue figures.
likely downward pressure as investors reassess revenue momentum
Guidance is below prior quarter and below expectations for growth, prompting sell‑side caution.
Market effects
Highlights challenges for the broader RNA therapeutics sector in sustaining revenue growth.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact beyond niche biotech community.
Counterpoint
Some investors may view the flat loss as a sign of disciplined cost control and maintain a bullish stance.
Key entities
- CompanyStoke Therapeutics
RNA medicine developer reporting Q3 earnings guidance.

